Abstract: An in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient for medical diagnostics purposes, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin, in particular a C-terminal peptide fragment.

Abstract: Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab?)2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.

Abstract: The present invention provides a novel compound having a phenanthroline structure represented by formula (I) or a salt thereof:

Abstract: The invention relates to a method for the diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency for NYHA I patients, wherein a determination of the proANP marker, NT-proANP marker, or fragments or partial peptides thereof is carried out parallel to a determination of BNP, proBNP, and/or NT-proBNP on patients to be examined.

Abstract: Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.

Abstract: The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event.

Abstract: The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from said subject; (ii) determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying said subjects into either of the categories: (a) responder to a medication for treatment of said disease, (b) non-responder to a medication for treatment of said disease not showing an unfavourable effect after having received said medication; (c) subjects showing an unfavourable effect after having received said medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention.

Abstract: The present invention relates to a method for the diagnosis or prognosis of a disease or clinical condition in a subject comprising the steps of: (i) providing a sample of bodily fluid of a subject, (ii) determining the level of peroxiredoxin 4 (PRX4) or a fragment thereof having at least 20 amino acids residues in length in said sample, and (iii) correlating the level of PRX4 or a fragment thereof with a disease or clinical condition.

Abstract: The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections.

Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.

Abstract: The present invention relates to a diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic.

Abstract: The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis.

Abstract: The field of the present invention is the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. It is a subject of the present invention to provide a method for the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea.

Abstract: The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.

Abstract: The invention relates to an in vitro method for detecting the formation of endothelins during serious illnesses, especially cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient for medical diagnosis. Using this method, relatively long-lasting peptide fragments, especially a C-terminal peptide fragment, of the processed primary prepro- or proendothelins that contain neither the actual biologically active endothelin nor its direct precursor, big endothelin, can be detected.

Abstract: Subject of the present invention are assays and in vitro methods for prediction of the progression of primary chronic kidney disease (CKD) or for monitoring chronic kidney disease therapy comprising the determination of the level of ANP and/or ADM or its precursors or fragments thereof.

Abstract: The present invention relates to an in vitro-method for diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in a subject, comprising the determination of the relative level of one or more cardiovascular markers in a sample of a subject and the use of the determined relative level of said one or more cardiovascular peptides for the diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in said subject.

Abstract: Subject of the present invention are assays and in vitro methods for the prediction of first coronary and cardiovascular events and biomarkers useful therein.

Abstract: Subject of the present invention are assays and in vitro methods for the prediction of the risk of a subject for contracting metabolic syndrome and/or diabetes mellitus and for diagnosing metabolic syndrome, comprising determining the level of arginine vasopressin pro-hormone or fragments thereof in a sample of a subject.

Abstract: Subject of the present invention is an in vitro-method for classifying a foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system of a subject, comprising determining the relative level of one or more cardiovascular markers.